dialogue with the public to increase awareness and understanding of nanotechnologies, as well as more stringent regulation and oversight of these technologies. Dr. Kulinowski noted that the cosmetic products that FDA does not have premarket approval over are generating much more controversy because there’s a perception that “there’s no one minding the store.” Several nongovernmental organizations have written reports and filed petitions for FDA to take a stronger approach toward these products, she said. “I would argue that concerns over drugs and medical devices are less because there’s a perception that FDA has different, more rigorous process for screening these drugs,” Dr. Kulinowski said.
Dr. Gaspar stressed that it is not just the general public that needs to be educated about nanotechnologies, but also policymakers. “Before you have a problem with the general public, you have a problem with people that are making uninformed decisions,” he said.